Gastric Cancer News and Research

RSS

NetApp, Stanford Genome Technology Center build gastric cancer registry powered by NetApp storage technology

Gastric cancer is the number two cancer killer worldwide and one of the top cancer killers in the U.S., but gastric cancer research gets the least federal funding of any type of cancer research. According to a CBS News analysis of data released by the American Cancer Society, for every cancer-related death in the U.S., only $1,168 federal research dollars are spent on gastric cancer, versus $18,870 for cancer of the cervix and $14,095 for breast cancer.

12 Jan 2010

Study explains how H. pylori infection causes stomach cancer

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.

7 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

New figures show there was a steady decline in cancer deaths in the European Union between 1990-1994 and 2000-2004.

1 Dec 2009

Study on deaths from cancer in Europe shows steady decline in mortality

New figures on deaths from cancer in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population.

29 Nov 2009

Erbitux drug can reverse rare stomach disorder, report researchers

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week.

25 Nov 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

African-Americans more likely to die from colorectal cancer than Caucasians, says new study

New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.

13 Nov 2009

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

4 Nov 2009

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Elevated expression of COX-2 is observed in a wide variety of human malignancies, including gastric cancer. Long-term high dose COX-2 inhibitors can inhibit gastric carcinogenesis in animal models, but the possible life-threatening cardiovascular adverse events limit its popular application. Therefore, it is important to evaluate the optimal intervention point of COX-2 inhibitors for inhibiting H. pylori-associated gastric carcinogenesis.

29 Oct 2009

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Moreover, in Asian countries such as Indonesia, Japan, China, and Thailand, where the H. pylori infection rates are similar, there is a significant difference regarding the outcome of gastric cancer. That fact has been termed the "Asian paradox".

29 Oct 2009

Genomics can provide insights in understanding emerging infectious disease

This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.

27 Oct 2009

Immune-related proteins are potential drug targets for gastric inflammation and cancer

A research team from South Korea studied the complex reaction of gastric inflammation induced by Helicobacter pylori (H pylori) in a systematic manner using a protein interaction network. Their study will be published on September 28, 2009 in the World Journal of Gastroenterology.

19 Oct 2009

Early detection of PGAP may reduce mortality rate

Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate.

19 Oct 2009

Gastric Cancer News and Research

NetApp, Stanford Genome Technology Center build gastric cancer registry powered by NetApp storage technology

Study explains how H. pylori infection causes stomach cancer

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

Study on deaths from cancer in Europe shows steady decline in mortality

Erbitux drug can reverse rare stomach disorder, report researchers

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Press conference highlights emerging treatments in pancreatic cancer

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

African-Americans more likely to die from colorectal cancer than Caucasians, says new study

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

Genomics can provide insights in understanding emerging infectious disease

Immune-related proteins are potential drug targets for gastric inflammation and cancer

Early detection of PGAP may reduce mortality rate

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News